JAZZ News and Press, Jazz Pharmaceuticals plc From 12/30/21

Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating JZP150 for Once-Daily Treatment of Adults with Post-Traumatic Stress Disorder U.S. FDA granted JZP150 Fast Track designation in PTSD, underscoring the unmet needs of patients If approv...

Jazz Pharmaceuticals (NASDAQ:JAZZ) announces that the first patient has been enrolled in a global Phase 2b clinical trial evaluating the safety and efficacy of suvecaltamide (also known as JZP385), for the potential treatment of moderate to severe essential tremor (ET), the most common m...

Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluating Novel Suvecaltamide (JZP385) for Once-Daily Treatment of Adults with Essential Tremor PR Newswire DUBLIN , Dec. 15, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nas...

PharmaMar and Jazz Pharmaceuticals Announce Initiation of Confirmatory Phase 3 Clinical Trial of Zepzelca® (lurbinectedin) for the Treatment of Patients with Relapsed Small Cell Lung Cancer The confirmatory trial is designed to secure full approval in the U.S. and serve as ...

Jazz Pharmaceuticals Presents Positive Interim Phase 2/3 Results of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at ASH 2021 Annual Meeting Rylaze maintains clinically meaningful level of asparagi...

One of the keys to finding new opportunities is discovering deep value – where investors have tossed everything overboard in a particular theme with no regard for long-term performance potential. Find those opportunities and you unlock enormous stores of long-term low risk return poten...

If you're looking to do some Christmas shopping on stocks, there are some incredibly good deals out there right now. The market isn't crashing, but some stocks have been struggling of late that you likely won't regret adding to your portfolio today if you're a long-term investor. Shares...

High on Growth: Cannabis REITs are far-and-away the best-performing REIT sector of the past half-decade as the budding industry thrives in the murky and often contradictory regulatory framework of legalized marijuana. Joining Innovative Industrial, Power REIT, and AFC Gamma, a pair of...

Jazz Pharmaceuticals to Present from Expanding Neuroscience Portfolio Epidiolex® (cannabidiol) Oral Solution Data at the 2021 American Epilepsy Society Annual Meeting Data from six abstracts advancing cannabidiol (CBD) research to be presented, including two abstracts which...

Jazz Pharmaceuticals Announces First Patient Enrolled in IMforte Phase 3 Trial Evaluating Zepzelca® (lurbinectedin) in Combination with a PD-L1 Inhibitor in Small Cell Lung Cancer Registrational trial will assess the potential for a novel combination therapy in extensive-st...